Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

I Duffy

Showing results (31-40 of 41) with videos related to

Pageof 5
Sort By:
Circulation. Heart Failure|October 26, 2018
Patient, Provider, and Practice Characteristics Associated With Sacubitril/Valsartan Use in the United StatesAdam D DeVore, C Larry Hill, Laine Thomas, et al.
Journal of Cardiac Failure|August 24, 2021
Treatment Persistence of Renin-Angiotensin-Aldosterone-System Inhibitors Over Time in Heart Failure with Reduced Ejection FractionMuthiah Vaduganathan, Gregg C Fonarow, Stephen J Greene, et al.
American Heart Journal|June 20, 2017
Change the management of patients with heart failure: Rationale and design of the CHAMP-HF registryAdam D DeVore, Laine Thomas, Nancy M Albert, et al.
Circulation. Cardiovascular Quality and Outcomes|April 9, 2018
Health Status Variation Across Practices in Outpatients With Heart Failure: Insights From the CHAMP-HF (Change the Management of Patients With Heart Failure) RegistryYevgeniy Khariton, Adrian F Hernandez, Gregg C Fonarow, et al.
JACC. Heart Failure|May 11, 2020
Contemporary Treatment Patterns and Clinical Outcomes of Comorbid Diabetes Mellitus and HFrEF: The CHAMP-HF RegistryMuthiah Vaduganathan, Gregg C Fonarow, Stephen J Greene, et al.
The American Journal of Cardiology|November 5, 2019
Comparison of Hydralazine/Nitrate and Angiotensin Receptor Neprilysin Inhibitor Use Among Black Versus Nonblack Americans With Heart Failure and Reduced Ejection Fraction (from CHAMP-HF)Erika M Giblin, Kirkwood F Adams, Larry Hill, et al.
Journal of the American College of Cardiology|July 21, 2018
Medical Therapy for Heart Failure With Reduced Ejection Fraction: The CHAMP-HF RegistryStephen J Greene, Javed Butler, Nancy M Albert, et al.
JACC. Heart Failure|September 16, 2019
Association Between Sacubitril/Valsartan Initiation and Health Status Outcomes in Heart Failure With Reduced Ejection FractionYevgeniy Khariton, Gregg C Fonarow, Suzanne V Arnold, et al.
JACC. Heart Failure|February 11, 2019
Target Doses of Heart Failure Medical Therapy and Blood Pressure: Insights From the CHAMP-HF RegistryPoghni A Peri-Okonny, Xiaojuan Mi, Yevgeniy Khariton, et al.
JACC. Heart Failure|June 10, 2019
Association of Changes in Heart Failure Treatment With Patients' Health Status: Real-World Evidence From CHAMP-HFMerrill Thomas, Yevgeniy Khariton, Gregg C Fonarow, et al.
Pageof 5

Showing results (31-40 of 41) with videos related to

Sort By:
Pageof 5
Circulation. Heart Failure|October 26, 2018
Patient, Provider, and Practice Characteristics Associated With Sacubitril/Valsartan Use in the United StatesAdam D DeVore, C Larry Hill, Laine Thomas, et al.
Journal of Cardiac Failure|August 24, 2021
Treatment Persistence of Renin-Angiotensin-Aldosterone-System Inhibitors Over Time in Heart Failure with Reduced Ejection FractionMuthiah Vaduganathan, Gregg C Fonarow, Stephen J Greene, et al.
American Heart Journal|June 20, 2017
Change the management of patients with heart failure: Rationale and design of the CHAMP-HF registryAdam D DeVore, Laine Thomas, Nancy M Albert, et al.
Circulation. Cardiovascular Quality and Outcomes|April 9, 2018
Health Status Variation Across Practices in Outpatients With Heart Failure: Insights From the CHAMP-HF (Change the Management of Patients With Heart Failure) RegistryYevgeniy Khariton, Adrian F Hernandez, Gregg C Fonarow, et al.
JACC. Heart Failure|May 11, 2020
Contemporary Treatment Patterns and Clinical Outcomes of Comorbid Diabetes Mellitus and HFrEF: The CHAMP-HF RegistryMuthiah Vaduganathan, Gregg C Fonarow, Stephen J Greene, et al.
The American Journal of Cardiology|November 5, 2019
Comparison of Hydralazine/Nitrate and Angiotensin Receptor Neprilysin Inhibitor Use Among Black Versus Nonblack Americans With Heart Failure and Reduced Ejection Fraction (from CHAMP-HF)Erika M Giblin, Kirkwood F Adams, Larry Hill, et al.
Journal of the American College of Cardiology|July 21, 2018
Medical Therapy for Heart Failure With Reduced Ejection Fraction: The CHAMP-HF RegistryStephen J Greene, Javed Butler, Nancy M Albert, et al.
JACC. Heart Failure|September 16, 2019
Association Between Sacubitril/Valsartan Initiation and Health Status Outcomes in Heart Failure With Reduced Ejection FractionYevgeniy Khariton, Gregg C Fonarow, Suzanne V Arnold, et al.
JACC. Heart Failure|February 11, 2019
Target Doses of Heart Failure Medical Therapy and Blood Pressure: Insights From the CHAMP-HF RegistryPoghni A Peri-Okonny, Xiaojuan Mi, Yevgeniy Khariton, et al.
JACC. Heart Failure|June 10, 2019
Association of Changes in Heart Failure Treatment With Patients' Health Status: Real-World Evidence From CHAMP-HFMerrill Thomas, Yevgeniy Khariton, Gregg C Fonarow, et al.
Pageof 5